Horizon Pharma PLC (NASDAQ: HZNP)
Horizon Pharma stock is up in a big way today. The company announced earlier today that it has revised its guidance for the second quarter and for the full year. Today, we’ll talk about the revised guidance, what affect it has had on the stock today, and what we can expect to see from HZNP moving forward. So, let’s get right to it…
HZNP Guidance Update
For the quarter, Horizon Pharma announced that they are expecting to produce revenue between $170 and $172 million. This figure is far higher than the $140.44 million analysts are expecting for the quarter. The company has also released compelling guidance with regard to full year revenue. They are expecting the full-year revenue to come in between $660 and $680 million; that’s up from previous guidance of between $590 and $610 million and far outpaces analyst expectations of $611.5 million. In the statement, HZNP explained that they are seeing accelerating prescription growth in their primary care and specialty business units; resulting in their improved guidance.
How The Market Is Reacting To The News
As we would imagine, the market is having an overwhelmingly positive reaction to the news. After all, investors are investing for growth; and HZNP is expecting to produce more growth than previously anticipated. With that said, HZNP is currently (12:39) trading at $38.48 per share after a gain of 3.78% so far today.
What We Can Expect To See From HZNP Moving Forward
Moving forward, I’m expecting more positive news from HZNP. First off, if earnings go as expected for the second quarter, the report is likely to prove to be a major catalyst for the stock. So, keep your eyes on it on August 6th as earnings are released. Also, with increasing guidance, investors are likely to put more faith into the stock now than before; so, I’m expecting to see more gains as we get closer to the earnings release.
What Do You Think?
Where do you think HZNP is headed and why? Let us know in the comments below!